During the last session, Kezar Life Sciences Inc (NASDAQ:KZR)’s traded shares were 1.08 million, with the beta value of the company hitting 0.46. At the end of the trading day, the stock’s price was $0.82, reflecting an intraday loss of -4.23% or -$0.04. The 52-week high for the KZR share is $3.16, that puts it down -285.37 from that peak though still a striking 18.29% gain since the share price plummeted to a 52-week low of $0.67. The company’s market capitalization is $58.26M, and the average intraday trading volume over the past 10 days was 1.05 million shares, and the average trade volume was 709.85K shares over the past three months.
Kezar Life Sciences Inc (NASDAQ:KZR) trade information
Kezar Life Sciences Inc (KZR) registered a -4.23% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.23% in intraday trading to $0.82, hitting a weekly high. The stock’s 5-day price performance is -9.06%, and it has moved by -20.27% in 30 days. Based on these gigs, the overall price performance for the year is -73.08%. The short interest in Kezar Life Sciences Inc (NASDAQ:KZR) is 3.38 million shares and it means that shorts have 3.91 day(s) to cover.
Kezar Life Sciences Inc (KZR) estimates and forecasts
Statistics show that Kezar Life Sciences Inc has underperformed its competitors in share price, compared to the industry in which it operates. Kezar Life Sciences Inc (KZR) shares have gone down -21.04% during the last six months, with a year-to-date growth rate less than the industry average at 3.82% against 13.70. In the rating firms’ projections, revenue will decrease -60.00% compared to the previous financial year.
Revenue for the current quarter is expected to be $500k as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to $750k by the end of Jun 2024.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 9.06%. While earnings are projected to return 1.86% in 2024.
KZR Dividends
Kezar Life Sciences Inc is due to release its next quarterly earnings between May 09 and May 13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Kezar Life Sciences Inc (NASDAQ:KZR)’s Major holders
Kezar Life Sciences Inc insiders own 14.81% of total outstanding shares while institutional holders control 67.98%, with the float percentage being 79.79%. Suvretta Capital Management, LLC is the largest shareholder of the company, while 109 institutions own stock in it. As of Jun 29, 2023, the company held over 7.17 million shares (or 9.86% of all shares), a total value of $17.56 million in shares.
The next largest institutional holding, with 6.08 million shares, is of Avidity Partners Management, LP’s that is approximately 8.36% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $14.9 million.
Also, the Mutual Funds coming in first place with the largest holdings of Kezar Life Sciences Inc (KZR) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 1.88 million shares. This amounts to just over 2.58 percent of the company’s overall shares, with a $4.6 million market value. The same data shows that the other fund manager holds slightly less at 1.6 million, or about 2.21% of the stock, which is worth about $2.39 million.
